Hallucinogenic drugs in psychiatric research and treatment: perspectives and prospects

The review situates contemporary human research with hallucinogens against a long history of cultural, recreational, and clinical use. Earlier work with lysergamides (notably LSD), phenethylamines (mescaline), and indolealkylamines (psilocybin, DMT) generated substantial clinical and psychopharmacological data in the mid-20th century but was interrupted for about a generation. The author emphasises three motivations for renewed research: (1) hallucinogens produce complex syndromes that probe many aspects of human cognition, affect, perception, and volition and so offer a window on mind–brain relationships; (2) drug-induced states overlap in some respects with endogenous psychoses, suggesting potential mechanistic and therapeutic insights; and (3) reports of psychotherapeutic enhancement, and continued recreational use and abuse, argue for better-characterised, safe clinical research and treatments for adverse sequelae. This article therefore aims to review the history, pharmacology, human experimental data, therapeutic applications, adverse effects, and regulatory context of classical and related hallucinogens, and to outline methodological, training, and future-research priorities for restarting human hallucinogen research. The author frames the review as both a synthesis of existing human data and a set of pragmatic recommendations for designing rigorous, state-of-the-art studies in the 1990s and beyond.

This is a narrative, integrative review drawing on historical reports, preclinical pharmacology, human psychopharmacology studies, clinical series, epidemiological data, and surveys of earlier clinical research. The extracted text does not provide a formal methods section describing search strategy, inclusion criteria, databases searched, or a systematic appraisal process; hence the review appears to be selective and discursive rather than a systematic review or meta-analysis with prespecified methods. The author summarises evidence from a variety of sources, including large historical clinical datasets (notably thousands of patients and volunteers exposed to LSD and mescaline in mid-century research), national survey data (NIDA statistics on adolescent LSD use), animal models (drug discrimination paradigms), human pharmacological challenge and blockade studies, psychometric instrument development (including the Hallucinogen Rating Scale, HRS), and contemporary Phase I and psychopharmacology protocols being undertaken at several US and European centres. Where available, quantitative counts and rates from prior surveys are reported; however, details of how studies were selected for inclusion in the review are not specified in the extracted text.

Historical clinical research: Large mid-20th-century clinical programmes administered LSD and related compounds to thousands of subjects (total exposures cited as over 25,000 doses in more than 5,000 subjects) and, when subjects were carefully screened, supervised, and followed, reported generally acceptable safety profiles. Early uncontrolled psychotherapeutic series suggested short-term clinical improvements in depression, substance abuse, autism, and palliative care, but methodological weaknesses (small samples, lack of controls and blinded raters, variable outcomes) limited definitive conclusions. Epidemiology and legal status: NIDA survey data cited an increase in 12-month LSD use among high school seniors from 4.8% to 5.6% between 1988 and 1992, contrasting with declines in some other drugs; lifetime hallucinogen prevalence approximated that for cocaine and exceeded heroin by several-fold. Hallucinogens are placed in Schedule I under US law, with attendant legal and regulatory constraints; religious exemptions (e.g. peyote in the Native American Church) and legislative developments are noted. Pharmacology and mechanisms: The review emphasises serotoninergic mechanisms, especially 5-HT1A and 5-HT2A/C receptor involvement, as central to classical hallucinogens' effects, while acknowledging roles for noradrenergic, dopaminergic and cholinergic systems. Tolerance and cross-tolerance develop rapidly for classical agents; DMT is an exception, showing little behavioural tolerance and producing full effects in LSD-tolerant subjects. Animal drug-discrimination models identify some limitations because non-hallucinogens can be LSD-like in animals, and psilocybin did not substitute reliably in certain paradigms, underscoring the need for human studies. Human measurement: Earlier rating instruments for LSD existed but had limitations. The author reports development of the Hallucinogen Rating Scale (HRS), drafted from interviews with experienced users and pilot DMT studies; the HRS groups items into six clinical clusters (somaesthesia, affect, perception, cognition, volition, and intensity) and is reported to be sensitive to dose-related subjective effects, sometimes more so than biological measures. Drug characteristics and administration: The review categorises hallucinogens by temporal profile (ultra-short to ultra-long acting), noting that pharmacokinetics and access to brain sites largely explain onset and duration. Routes of administration (intravenous, intramuscular, oral, intraspinal) influence time course, and there is debate about downstream mechanisms but evidence for very rapid onset under some routes. Hallucinogens and psychosis: Findings on similarity to schizophrenia are mixed. Acute positive-symptom patients show more overlap with psychedelic phenomena than chronic negative-symptom patients, who often show blunted responses. The DMT/short-chain tryptamines have been considered putative endogenous ‘schizotoxins’ because of biochemical plausibility and some correlative data, but peripheral measures have not consistently differed between patients and controls. Psychotherapy studies: Two broad therapeutic models are described. The psycholytic approach used repeated low-to-moderate doses adjunctive to ongoing psychotherapy, while the psychedelic model used one or a few high-dose sessions to elicit peak or mystical-type experiences. Earlier uncontrolled reports suggested benefit in substance abuse, palliative care, and other conditions, but controlled studies and longer follow-up often attenuated those positive impressions; a review of 31 alcoholism studies was inconclusive given methodological heterogeneity. Adverse effects: Adverse outcomes are categorised as acute (brief panic reactions, psychotic reactions requiring hospitalisation), subacute (flashbacks; reported incidence ranges widely, with 15%–77% in some series, though DMT studies reported 5%–10% in experienced volunteers), and chronic (functional syndromes resembling enduring negative-symptom disorders, persistent perceptual disorders). A survey of clinical research reported very low rates of attempted or completed suicide in normal volunteers (0/1,000) and low but non-zero rates in patient populations (attempted 1.2/1,000, completed 0.4/1,000), with psychotic reactions over 48 hours of 0.8/1,000 in volunteers and 1.8/1,000 in patients. Data on mutagenicity and teratogenicity were inconsistent and not replicated; the author advises excluding pregnant women or those not using reliable contraception. Contemporary and ongoing research: At the time of writing, Phase I and psychopharmacology studies with DMT, ibogaine, MDMA, ketamine, psilocybin and mescaline were underway at multiple US and European centres; some European clinical psychodynamic work had been ongoing without published outcome data. Identified future research priorities include exploiting different temporal profiles of drugs for specific experimental goals, refining measurement (subjective measures such as HRS shown to be sensitive), exploring non-serotonergic mechanisms (notably dopamine), combining pharmacological blockade studies, structure–activity work, and advanced brain imaging and electrophysiology.

The author interprets the body of evidence as supportive of cautious renewal of human hallucinogen research, arguing that these compounds can illuminate mind–brain interfaces, generate mechanistic hypotheses relevant to psychoses, and potentially augment psychotherapeutic interventions. While acknowledging promising signals from earlier clinical work, the review stresses that many of those studies lacked adequate controls, independent raters, standardised outcomes, and sufficient follow-up; placebo and dosing issues complicate interpretation of past psychotherapeutic findings. Practical concerns and recommendations receive considerable emphasis. The author urges rigorous subject selection, preparation, supervision, and follow-up; use of experienced hallucinogen users in early psychopharmacology research to improve informed consent and reduce traumatic reactions; use of the lowest effective doses for clinical populations; and stepwise dosing if high-dose sessions are necessary. Training and supervisory arrangements for investigators are recommended, with a call for specialised training or certification to reduce risks arising from transference/countertransference, suggestibility, and potential ethical boundary violations. The review also highlights the importance of set and setting—participants' expectations, personality, and the physical and interpersonal environment—and recommends that these variables be explicitly considered in study design. For future research, the author proposes methodological innovations: standardised subjective instruments (HRS), within-subject designs for sensitivity, pharmacological blockade and pretreatment studies to understand mechanism and to develop interventions for acute adverse reactions, comparative within-subject evaluations of congeners to define structure–activity relationships, and application of modern neuroimaging and electrophysiological techniques. Clinical avenues proposed include hybrid psychotherapeutic models that combine psycholytic and psychedelic elements, studies in palliative care and PTSD, and carefully controlled substance-abuse interventions. The author also notes legal and regulatory hurdles and calls for careful engagement with oversight agencies. Limitations acknowledged include the selective and often anecdotal nature of much historical data and the absence of standardised methods in many earlier trials, which constrain the strength of conclusions and necessitate contemporary, methodologically rigorous studies.

Renewal of human hallucinogen research is encouraging but must be pursued cautiously. The author concludes that contemporary studies should employ state-of-the-art methodologies, meticulous selection, screening, preparation, supervision, and follow-up of subjects, and explicit attention to the training and characteristics of investigators and the research setting. Given the controversial history and potential for serious psychiatric sequelae, these procedural safeguards and regulatory oversight are essential for safe and scientifically valid progress in the field.